Together we inspire and empower one another to do our best work. We all want to deliver hope to every patient and it is this shared passion that defines the spirit of Meizon.
Liz brings over 30 years of experience in commercial operations, successfully leading start-up SMEs in the life sciences sector. Liz is also Co-Founder of Esfam Biotech. She excels in corporate governance, capital allocation, and portfolio management, with a strong background in project management. Liz is skilled in human resources and M&A, adept at managing organizational change and fostering positive workplace culture. Her fundraising expertise has been crucial in securing capital, driving business growth, and innovation. Additionally, Liz offers external business consulting, providing strategic insights to help organizations achieve their goals. Her versatile leadership has consistently led to successful outcomes.
She is a Harvard Business School Alumni, completed the PLD (accelerated eMBA) program. A/Prof. Wah Chin Boon leads the Steroid Neurobiology group at the Florey Institute of Neuroscience & Mental Health. With a PhD in Biochemistry from the National University of Singapore, her research delves into the effects of neurosteroids and fatty acids on brain function and behaviour. A prolific researcher, A/Prof. Wah Chin Boon has published over 65 papers, amassing more than 4300 citations, particularly noted for her work in fat and cholesterol metabolism. Her seminal discovery of a unique medium chain fatty acid that reverses autistic-like traits in mouse models positions her work as a potential breakthrough in Autism treatment.
Prof. Albert Frauman is a leading expert in Clinical Pharmacology & Therapeutics at the University of Melbourne and the Director of Clinical Pharmacology at Austin Hospital. With over 40 years as a trained endocrinologist, he previously served as the Medical Director at Nucleus Network. Since 2007, he has been a member of the Human Research Ethics Committee and a research integrity advisor for Austin Health. He has authored over 70 peer-reviewed publications with over 1,000 citations in autoimmunity, viral infection, and cancer biomarkers. Prof. Albert Frauman is also a co-founder and Director of Esfam Biotech.
Sean is a strategic leader with founding roles in healthcare across Australia, Asia, and the USA. As a Fellow of the Institute of Chartered Accountants in Australia and New Zealand and a Chartered Tax Advisor, he has held multiple CFO and corporate advisory positions. Sean serves on boards and advisory roles for various global businesses, ranging from professional services to healthcare. He is a founding director of Miskawaan Health Group, which operates medical clinics across Europe and Asia. Additionally, Sean founded and served as CEO of United Dental Corporation, partnering with leading dentists in the USA.
Prof. Anne-Louise Ponsonby is the Division Head for the Early Brain Science Department and Head of Neuroepidemiology Research at the Florey Institute for Neuroscience & Mental Health. She founded and co-leads key study platforms like the Ausimmune Study and Barwon Infant Study cohort, which integrate advanced analytics with multidimensional data. Her international collaborations have strengthened Australia’s ability to assess human health effects of chemical mixtures (ENDPoint Consortium), conduct epigenetic analyses (Karolinska Institute, Sweden), and apply innovative methods to birth cohorts (GUSTO, Singapore). Her work is pivotal in advancing brain science and neuroepidemiology research.
Prof. Poessner is the Director of Research Initiatives and Infrastructure at the Australian National University. She holds a PhD from the Max-Planck-Institute for Molecular Plant Physiology, Germany. Formerly, she was Head of the School of BioSciences and Lab Head of Biochemistry at the University of Melbourne. Recognized as a world leader in metabolomics and lipidomics, her research has been pivotal in biological sciences, systems biology, and biomarker discovery. With over 160 publications and more than 13,000 citations, Prof. Poessner's work has made a substantial impact on her field.
Prof. Ashley Bush is the Director of the Melbourne Dementia Research Centre and Head of the Oxidation Biology Unit. He is renowned for his groundbreaking work on the role of metal biology in neurodegenerative diseases. His research has highlighted disturbances in brain metal homeostasis, offering new insights into the pathogenesis of Alzheimer’s disease and other conditions such as amyotrophic lateral sclerosis, Parkinson’s disease, and Huntington’s disease. Prof. Ashley Bush’s contributions have significantly advanced the understanding of neurodegeneration and shifted the field’s focus towards the critical role of metal balance in brain health.
Jenny Petering is a registered Australian and New Zealand Patent Attorney and a leading figure in the Australian biotechnology industry. With 15 years as a partner at FB Rice, She now serves as Counsel, focusing on advancing the biotech sector. She is also a Senior Fellow in the Melbourne Law Masters program at Melbourne University and hold various biotechnology industry mentoring roles. Additionally, Jenny Petering is a Scale Angel member, Which funds and support early-stage STEM companies. Her extensive experience and contributions have significantly impacted both legal practice and the biotechnology community.
Prof. Dr. Michael Rossbach is a seasoned life and health sciences professional with expertise in immunology, diagnostics, cell-based therapeutics, neuroscience, and genomics. He is the founder and Managing Partner of Ikxinta, an advisory firm with a global presence in the USA, Portugal, Germany, Singapore, and China. He holds academic positions at the National University of Singapore, Technical University of Munich (TUM Asia), and INSEAD Management School as an Entrepreneur-in-Residence. Additionally, he is a Professor at the Witten School of Management in Germany and an elected member of the Scientific Council of the Deutsches Elektronen-Synchrotron DESY, part of Germany’s largest research center.
James LaFlamme is the former Chief Executive Officer and Founder of Biopharma Global. With over 30 years of healthcare operational experience, he has held roles including CEO, COO, VP of Clinical Services, and Administrative Director across various hospitals and health systems. As CEO of BioPharma Global, he led global operations, managing advisory services and client development. He previously served as EVP at Coté Orphan, overseeing regulatory affairs and business development, and held roles as VP at the National Committee for Quality Assurance (NCQA) and Director of the Healthcare Advisory Public Sector Practice at PwC.
Peter has over 30 years of strategic leadership in healthcare, pharmaceuticals, and biotech. His career, driven by a passion for health, has spanned the pharmaceutical, healthcare, and biotechnology industries, where he has gained extensive knowledge and expertise across various therapeutic and medical sectors in both local and international markets. Starting as a sales representative and advancing to Chief Operating Officer, Peter possesses a comprehensive understanding of the intricate biotech, life sciences, healthcare, and pharmaceutical industries. His experience covers the full spectrum of these sectors, providing him with unique insights into their complexities and challenges.
Together we are bringing hope and aim to provide relief to millions around the world.
Investing in Meizon Innovation is investing in the future of healthcare. We are at a pivotal moment, moving towards clinical trials for DL33 and MO8 and we need your support to make this vision a reality.
Copyrights @ meizon 2024 Reserved
Copyrights @ meizon 2024 Reserved
Website by Avanttech
